| Detailed information |
|---|
| CancerLivER ID | 2584 |
| Biomarker | OAS2, ADH1A, FLJ20378, HSF2, PSME1, E2L6, UBE2L6, STAT1, LIM, FLN29, GABARAPL1, |
| Biomarker Name/Symbol (given in Publication) | 2,5-oligoadenylate synthetase 2 or OAS2, Class I alcohol dehydrogenase alpha subunit or ADH1A, Hypothetical protein FLJ20378 or , Signal transducer and activator of transcription 1 or STAT1, Heat shock transcription factor 2 or HSF2, Proteasome activator subunit1 or PSME1, Potassium inwardly-rectifying channel subfamily J, Proteasome activator subunit1 or PSME1, Ubiquitin-conjugating enzyme E2L6 or UBE2L6, Signal transducer and activator of transcription 1 or STAT1, LIM protein or LIM, FLN 29 gene product or FLN29, Signal transducer and activator of transcription 1 or STAT1, GABA(A) receptor-associated protein like 1 or GABARAPL1, Signal transducer and activator of transcription 1 or STAT1 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker for grade progression of HCC and associated invasion and with metastsis of HCC; but not validated on indepedent dataset |
| Experimental Condition | G1 (well differentiated) HCV-HCC v/s G2 (moderately differentiated) HCV-HCC; associated with invasion or metastsis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in G2 than G1 (with fisher ratio more than 1.7) |
| Level of significance | P < 0.005 |
| Source | Tissue |
| PMID | 15710396 |
| Type of Biomarker | Prognostic |
| Pathway | pathogenesis of HCV-related HCC and not HBV-associated HCC |
| Cohort | 76 HCC samples : 50 were sero- positive for HCV antibody (HCVAb) and seronegative for hepatitis B virus surface antigen (HBsAg) and among 50 (7G1 (well differentiated, 35 G2 (moderately differentiated) and 10 G3 (poorly differentiated); 26 were seronegative for HCVAb |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Hepatocellular carcinoma (HCC) samples with positive hepatitis C virus (HCV) serology (well (G1), moderately (G2), and poorly (G3) differentiated tumors) with and without HCV infection. |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |